Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Brigatinib

302989b4-650f-522b-b936-a293f74cd6d8 · FDA Approved · targets ALK

Brigatinib

MeasuredReference

Brigatinib targets CAMK2D, ERBB2_HER2, CAMK2A. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

CAMK2DERBB2_HER2CAMK2ACHEK2CLK1

Top hallmarks

  • tumor promoting inflammation7.2k
  • proliferation5.9k
  • evading apoptosis5.7k

Top pathways disrupted

No pathway data.

Resistance landscape — Brigatinib

MeasuredReference

1 known oncogenic variants exist on Brigatinib's top targets — see detail for inhibition impact.

Open in new tab